DOJ’s Stethoscope Sends UnitedHealth to the Stock Market ICU
UnitedHealth’s Medicare Fraud Probe Sparks Market Turmoil
UnitedHealth Group (UNH) shares cratered 16% on Thursday, May 15, 2025, plunging to a five-year low after a Wall Street Journal report unveiled a U.S. Department of Justice criminal investigation into potential Medicare fraud. For the health insurance giant, already staggering from a barrage of setbacks, this news is a gut punch that’s sent investors running for cover.
The DOJ probe is the latest chapter in UnitedHealth’s unfolding drama. A civil fraud investigation into its Medicare practices surfaced in February, followed by U.S. Senator Chuck Grassley’s inquiry into the company’s billing methods. Toss in CEO Andrew Witty’s sudden exit, a scrapped 2025 forecast that triggered an 18% stock drop on Tuesday, and soaring medical costs, and it’s no wonder the company’s stock is in freefall. A recent lawsuit accusing major insurers of paying kickbacks to brokers only adds fuel to the fire. “The stock is already in the doghouse with investors, and additional uncertainty will only pile on,” said James Harlow, senior vice president at Novare Capital Management, a UnitedHealth shareholder.
The market carnage has been staggering. Thursday’s plunge alone hacked billions off UnitedHealth’s market cap, with the past month’s selloff wiping out nearly $300 billion—over half its value since its November peak. If losses persist, UnitedHealth could be the S&P 500’s worst performer in two of the last three days. The pain rippled across the industry, dragging down rivals like CVS Health, Centene, Elevance, and Humana by 2% to 6%. “UnitedHealth Group is mired in a crisis seemingly without end,” said Susannah Streeter, head of money and markets at Hargreaves Lansdown.
UnitedHealth insists it hasn’t been formally notified of the DOJ’s criminal probe, but its tight-lipped response hasn’t soothed jittery investors. Still, some analysts see a silver lining. “Despite recent challenges, the company’s fundamentals remain sound,” noted Oppenheimer’s Michael Wiederhorn, though he cautioned that rebuilding market confidence will take time. UnitedHealth has long dominated the insurance and Medicare markets, but with regulators closing in and trust eroding, its path forward looks treacherous.
The DOJ probe’s details are murky, and its outcome is anyone’s guess. For now, UnitedHealth’s woes serve as a stark reminder: even titans can stumble. Investors are left wondering if this is rock bottom—or if the worst is yet to come.